AT
Attovia TherapeuticsAttovia Therapeutics is a clinical-stage biotech developing ATTOBODY-based biotherapeutics for immune-mediated diseases that went public on Nasdaq in August 2026 in an upsized IPO raising ~$332M gross.
8 Pulse stories
EM
Encore MedicalEncore Medical develops transcatheter septal occlusion devices to repair structural heart defects like patent foramen ovale (PFO).
2 Pulse stories
Total Raised
~$588M ($256M private + $332M IPO gross incl. greenshoe, Aug 2026)
Attovia TherapeuticsEncore Medical
Last Valuation
$767M at IPO pricing; ~$904M market cap at Nasdaq open (Aug 5, 2026)
Attovia TherapeuticsEncore Medical
Biotech
Sector
Biotech
2023
Founded
2017
San Carlos, CA
HQ
Eagan, Minnesota
Public (ATTO)
Status
Public (EMI)
Attovia Therapeutics investors
venBio PartnersGoldman Sachs AlternativesFrazier Life SciencesDeep Track CapitalIllumina VenturesSanofi VenturesEcoR1 Capital
Encore Medical investors
No investors on record.
Data from Value Add Pulse coverage and company research — see the full threads for Attovia Therapeutics and Encore Medical.